Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives

References

• International Agency for Cancer ResearchGLOBOCAN 2008 [webpage on the Internet] http://globocan.iarc.frAccessed October 4, 2013
   Google Scholar
• El-SeragHBHepatocellular carcinomaN Engl J Med2011365121118112721992124
   PubMed Web of Science ®Google Scholar
• FornerALlovetJMBruixJHepatocellular carcinomaLancet201237998221245125522353262
   PubMed Web of Science ®Google Scholar
• StarleyBQCalcagnoCJHarrisonSANonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connectionHepatology20105151820183220432259
   PubMed Web of Science ®Google Scholar
• WilhelmSMCarterCTangLBAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesisCancer Res200464197099710915466206
   PubMed Web of Science ®Google Scholar
• WilhelmSCarterCLynchMDiscovery and development of sorafenib: a multikinase inhibitor for treating cancerNat Rev Drug Discov200651083584417016424
   PubMed Web of Science ®Google Scholar
• LlovetJMRicciSMazzaferroVSHARP Investigators Study GroupSorafenib in advanced hepatocellular carcinomaN Engl J Med2008359437839018650514
   PubMed Web of Science ®Google Scholar
• ChengALKangYKChenZEfficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialLancet Oncol2009101253419095497
   PubMed Web of Science ®Google Scholar
• ChengALKangYKLinDYSunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trialJ Clin Oncol201331324067407524081937
   PubMed Web of Science ®Google Scholar
• CainapCQinSHuangWTPhase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)J Clin Oncol201331Suppl 4 Abs 249
   Web of Science ®Google Scholar
• JohnsonPJQinSParkJWBrivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL studyJ Clin Oncol201331283517352423980084
   PubMed Web of Science ®Google Scholar
• ZhuAXRosmorducOEvansJSEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with hepatocellular carcinoma (HCC)ESMO Congress2012 Abs 917
   Google Scholar
• ChengALShenYCZhuAXTargeting fibroblast growth factor receptor signaling in hepatocellular carcinomaOncology2011815–637238022269894
   PubMed Web of Science ®Google Scholar
• CasanovasOHicklinDJBergersGHanahanDDrug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumorsCancer Cell20058429930916226705
   PubMed Web of Science ®Google Scholar
• BergersGHanahanDModes of resistance to anti-angiogenic therapyNat Rev Cancer20088859260318650835
   PubMed Web of Science ®Google Scholar
• LiuLCaoYChenCSorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5Cancer Res20066624118511185817178882
   PubMed Web of Science ®Google Scholar
• ChenKFTaiWTLiuTHSorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3Clin Cancer Res201016215189519920884624
   PubMed Web of Science ®Google Scholar
• TaiWTChengALShiauCWSignal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinomaJ Hepatol20115551041104821354226
   PubMed Web of Science ®Google Scholar
• TaiWTShiauCWChenPJDiscovery of novel Src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinomaHepatology201459119020123908138
   PubMed Web of Science ®Google Scholar
• OuDLShenYCYuSLInduction of DNA damage-inducible gene GADD45beta contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cellsCancer Res201070229309931821062976
   PubMed Web of Science ®Google Scholar
• GedalyRAnguloPHundleyJPI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathwaysAnticancer Res201030124951495821187475
   PubMed Web of Science ®Google Scholar
• GedalyRAnguloPChenCThe role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatmentAnticancer Res20123272531253622753710
   PubMed Web of Science ®Google Scholar
• LachenmayerAAlsinetCSavicRWnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenibClin Cancer Res201218184997500722811581
   PubMed Web of Science ®Google Scholar
• LiuLPHoRLChenGGLaiPBSorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinomaClin Cancer Res201218205662567122929805
   PubMed Web of Science ®Google Scholar
• ZhaoDZhaiBHeCUpregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cellsCell Signal20142651030103924486412
   PubMed Web of Science ®Google Scholar
• HikitaHTakeharaTShimizuSThe Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenibHepatology20105241310132120799354
   PubMed Web of Science ®Google Scholar
• OuDLShenYCLiangJDInduction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinomaClin Cancer Res200915185820582819737956
   PubMed Web of Science ®Google Scholar
• ChiouJFTaiCJWangYHLiuTZJenYMShiauCYSorafenib induces preferential apoptotic killing of a drug- and radio-resistant Hep G2 cells through a mitochondria-dependent oxidative stress mechanismCancer Biol Ther20098201904191319770576
   PubMed Web of Science ®Google Scholar
• CoriatRNiccoCChéreauCSorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivoMol Cancer Ther201211102284229322902857
   PubMed Web of Science ®Google Scholar
• GalmicheAEzzoukhryZFrançoisCBAD, a proapoptotic member of the BCL2 family, is a potential therapeutic target in hepatocellular carcinomaMol Cancer Res2010881116112520647330
   PubMed Web of Science ®Google Scholar
• ShiYHDingZBZhouJTargeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosisAutophagy20117101159117221691147
   PubMed Web of Science ®Google Scholar
• LiXFGongRYWangMSorafenib down-regulates c-IAP expression post-transcriptionally in hepatic carcinoma cells to suppress apoptosisBiochem Biophys Res Commun2012418353153622285185
   PubMed Web of Science ®Google Scholar
• SonntagRGasslerNBangenJMTrautweinCLiedtkeCPro-apoptotic Sorafenib signaling in murine hepatocytes depends on malignancy and is associated with PUMA expression in vitro and in vivoCell Death Dis20145e103024481444
   PubMed Web of Science ®Google Scholar
• CaoMXuYYounJIKinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer modelLab Invest201191459860821321535
   PubMed Web of Science ®Google Scholar
• CabreraRAraratMXuYImmune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinomaCancer Immunol Immunother201362473774623223899
   PubMed Web of Science ®Google Scholar
• WangQYuTYuanYSorafenib reduces hepatic infiltrated regulatory T cells in hepatocellular carcinoma patients by suppressing TGF-beta signalJ Surg Oncol2013107442242722833259
   PubMed Web of Science ®Google Scholar
• ZhangQBSunHCZhangKZSuppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinomaPLoS One201382e5594523409093
   PubMed Web of Science ®Google Scholar
• SprinzlMFReisingerFPuschnikASorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cellsHepatology20135762358236823424039
   PubMed Web of Science ®Google Scholar
• ChenMLYanBSLuWCSorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunityInt J Cancer2014134231933123818246
   PubMed Web of Science ®Google Scholar
• ChenYHuangYReibergerTDifferential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in miceHepatology20145941435144724242874
   PubMed Web of Science ®Google Scholar
• OgasawaraSKanaiFObiSSafety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinomaHepatol Int20115385085621484134
   PubMed Web of Science ®Google Scholar
• Di CostanzoGGTortoraRIodiceLSafety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practiceDig Liver Dis201244978879222579445
   PubMedGoogle Scholar
• IavaroneMCabibboGPiscagliaFSOFIA (SOraFenib Italian Assessment) study groupField-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in ItalyHepatology20115462055206321898496
   PubMed Web of Science ®Google Scholar
• EbosJMLeeCRCruz-MunozWBjarnasonGAChristensenJGKerbelRSAccelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesisCancer Cell200915323223919249681
   PubMed Web of Science ®Google Scholar
• SaccoRBargelliniIGinanniBLong-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice?Expert Rev Anticancer Ther201212786987522845401
   PubMed Web of Science ®Google Scholar
• LencioniRKudoMYeSLGIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysisInt J Clin Pract201468560961724283303
   PubMed Web of Science ®Google Scholar
• NakanoMTanakaMKuromatsuREfficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinomaOncology201384210811423147476
   PubMed Web of Science ®Google Scholar
• ShinginaAHashimAMHaqueMIn a ‘real-world’, clinic-based community setting, sorafenib dose of 400 mg/day is as effective as standard dose of 800 mg/day in patients with advanced hepatocellular carcimona, with better tolerance and similar survivalCan J Gastroenterol201327739339623862169
   PubMed Web of Science ®Google Scholar
• KudoMUeshimaKArizumiTReal-life clinical practice with sorafenib in advanced hepatocellular carcinoma: a single-center experienceDig Dis201230660961623258103
   PubMed Web of Science ®Google Scholar
• Abou-AlfaGKSchwartzLRicciSPhase II study of sorafenib in patients with advanced hepatocellular carcinomaJ Clin Oncol200624264293430016908937
   PubMed Web of Science ®Google Scholar
• Abou-AlfaGKAmadoriDSantoroASafety and efficacy of sorafenib in patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B cirrhosisGastrointest Cancer Res201142404421673874
   PubMedGoogle Scholar
• PressianiTBoniCRimassaLSorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysisAnn Oncol201324240641123041587
   PubMed Web of Science ®Google Scholar
• RimassaLPressianiTBoniCA phase II randomized dose escalation trial of sorafenib in patients with advanced hepatocellular carcinomaOncologist201318437938023580239
   PubMed Web of Science ®Google Scholar
• HollebecqueACattanSRomanoOSafety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh scoreAliment Pharmacol Ther201134101193120121958438
   PubMed Web of Science ®Google Scholar
• WörnsMAWeinmannAPfingstKSafety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosisJ Clin Gastroenterol200943548949519247201
   PubMed Web of Science ®Google Scholar
• PinterMSieghartWGraziadeiISorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosisOncologist2009141707619144684
   PubMed Web of Science ®Google Scholar
• OzenneVParadisVPernotSTolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenibEur J Gastroenterol Hepatol20102291106111020300004
   PubMed Web of Science ®Google Scholar
• WörnsMAKochSNiederleIMThe impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenibDig Liver Dis201345540841323182599
   PubMedGoogle Scholar
• KimHYParkJWJooJWorse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinomaJ Gastroenterol Hepatol201328111756176123800278
   PubMed Web of Science ®Google Scholar
• KøstnerAHSorensenMOlesenRKGrønbækHLassenULadekarlMSorafenib in advanced hepatocellular carcinoma: a nationwide retrospective study of efficacy and tolerabilityScientific World Journal2013201393197223431262
   PubMed Web of Science ®Google Scholar
• PawlikTMReyesDKCosgroveDKamelIRBhagatNGeschwindJFPhase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinomaJ Clin Oncol201129303960396721911714
   PubMed Web of Science ®Google Scholar
• ParkJWKohYHKimHBPhase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinomaJ Hepatol20125661336134222314421
   PubMed Web of Science ®Google Scholar
• SieghartWPinterMReiseggerMConventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot studyEur Radiol20122261214122322215073
   PubMed Web of Science ®Google Scholar
• ChungYHHanGYoonJHInterim analysis of START: Study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trialInt J Cancer2013132102448245823129123
   PubMed Web of Science ®Google Scholar
• SansonnoDLaulettaGRussiSConteducaVSansonnoLDammaccoFTransarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trialOncologist201217335936622334456
   PubMed Web of Science ®Google Scholar
• KudoMImanakaKChidaNPhase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinomaEur J Cancer201147142117212721664811
   PubMed Web of Science ®Google Scholar
• LencioniRLlovetJMHanGSorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): phase II, randomized, double-blind SPACE trialJ Clin Oncol201230Suppl 4 Abs LBA154
   Web of Science ®Google Scholar
• HsuCPo-Ching-LiangMoritaSHuFCChengALPerspectives on the design of clinical trials combining transarterial chemoembolization and molecular targeted therapyLiver Cancer201213–416817624159581
   PubMed Web of Science ®Google Scholar
• ShenYCLinZZHsuCHHsuCShaoYYChengALClinical trials in hepatocellular carcinoma: an updateLiver Cancer201323–434536424400222
   PubMed Web of Science ®Google Scholar
• VillanuevaAHernandez-GeaVLlovetJMMedical therapies for hepatocellular carcinoma: a critical view of the evidenceNat Rev Gastroenterol Hepatol2013101344223147664
   PubMed Web of Science ®Google Scholar
• News Room on March 11, 2014Bayer and Onyx report Phase 3 study results of NEXAVAR^® (sorafenib) as adjuvant treatment for patients with liver cancer who have undergone surgery or local ablation [webpage on the Internet] Available from: http://pharma.bayer.com/html/pdf/STORM_Release_FINAL.pdfAssessed March 12, 2014
   Google Scholar
• Abou-AlfaGKJohnsonPKnoxJJDoxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trialJAMA2010304192154216021081728
   PubMed Web of Science ®Google Scholar
• HsuCHShenYCLinZZPhase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinomaJ Hepatol201053112613120416968
   PubMed Web of Science ®Google Scholar
• LeeSJLeeJParkSHPhase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinomaInvest New Drugs20123041540154721695438
   PubMed Web of Science ®Google Scholar
• Rojas-HernandezCMPattYZFekrazadMHSteinbergKARoachMLeeFCPhase II trial of sorafenib (S) and capecitabine (C) for hepatocellular carcinoma (HCC) in cirrhotic patients (pts)J Clin Oncol201331Suppl 15 Abs e15131
   Web of Science ®Google Scholar
• AssenatEBoigeVThézenasSSorafenib (S) alone versus S combined with gemcitabine and oxaliplatin (GEMOX) in first-line treatment of advanced hepatocellular carcinoma (HCC): Final analysis of the randomized phase II GONEXT trial (UNICANCER/FFCD PRODIGE 10 trial)J Clin Oncol201331Suppl 15 Abs 4028
   Web of Science ®Google Scholar
• YauTCCheungFYLeeFA multicenter phase II study of sorafenib, capecitabine, and oxaliplatin (SECOX) in patients with advanced hepatocellular carcinoma: Final results of Hong Kong-Singapore Hepatocellular Carcinoma Research Collaborative Group studyJ Clin Oncol201331Suppl 15 Abs 4117
   Web of Science ®Google Scholar
• LimHYYenCJTakWYA phase II trial of MEK inhibitor BAY 86-9766 in combination with sorafenib as first-line systemic treatment for patients with unresectable hepatocellular carcinoma (HCC)J Clin Oncol201230Suppl 15 Abs 4103
   Google Scholar
• ChooSPNgQSChenWJJA phase I/II study of AZD6244 in combination with sorafenib in advanced hepatocellular carcinomaJ Clin Oncol201230Suppl 15 Abs 4100
   Google Scholar
• FinnRSPoonRTYauTPhase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinomaJ Hepatol20135961271127723928403
   PubMed Web of Science ®Google Scholar
• KelleyRKNimeiriHSMunsterPNTemsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlatesAnn Oncol20132471900190723519998
   PubMed Web of Science ®Google Scholar
• FaivreSJFartouxLBouattourMA phase I study of AVE1642, a human monoclonal antibody-blocking insulin-like growth factor-1 receptor (IGF-1R), given as a single agent and in combination with sorafenib as first-line therapy in patients with advanced hepato cellular carcinoma (HCC)J Clin Oncol201129Suppl 4 Abs 270
   Web of Science ®Google Scholar
• LeeASZeeBCCheungFYRandomized phase II study of the x-linked inhibitor of apoptosis (XIAP) antisense AEG35156 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC)J Clin Oncol201230Suppl 15 Abs 4105
   Web of Science ®Google Scholar
• SunWNelsonDAlbertsSRPhase Ib study of mapatumumab in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) and chronic viral hepatitisJ Clin Oncol201129Suppl 4 Abs 261
   Web of Science ®Google Scholar
• ChengALKangYKByooBYPhase Ib dose-escalation study of a phase II randomized trial to assess the safety and tolerability of tigatuzumab (CS-1008) in combination with sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC)J Clin Oncol201230Suppl 15 Abs e14617
   Web of Science ®Google Scholar
• BitzerMGianniniEGHorgerMEfficacy, tolerability and pharmacokinetics of the oral histone deacetylase inhibitor resminostat in patients with advanced hepatocellular carcinoma: clinical data from the phase II SHELTER studyILCA Annual Conference2012 Abs O-030
   Google Scholar
• O’NeilBHBendellJCModianoMRPhase I/II study of E7050 (golvantinib) in combination with sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC): Phase I resultsJ Clin Oncol201331Suppl 4 Abs 294
   Web of Science ®Google Scholar
• MengXWLeeSHDaiHMcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitizationJ Biol Chem200728241298312984617698840
   PubMed Web of Science ®Google Scholar
• RosatoRRAlmenaraJACoeSGrantSThe multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulationCancer Res200767199490950017909059
   PubMed Web of Science ®Google Scholar
• RicciMSKimSHOgiKReduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced deathCancer Cell2007121668017613437
   PubMed Web of Science ®Google Scholar
• EzzoukhryZLouandreCTrécherelEEGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenibInt J Cancer2012131122961296922514082
   PubMed Web of Science ®Google Scholar
• Blivet-Van EggelpoëlMJChettouhHFartouxLEpidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cellsJ Hepatol201257110811522414764
   PubMed Web of Science ®Google Scholar
• ShaoYYHsuCHChengALPredictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: where are we?Liver Cancer2013229310724159601
   PubMed Web of Science ®Google Scholar
• LiMZhaoHZhangXInactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinomaNat Genet201143982882921822264
   PubMed Web of Science ®Google Scholar
• GuichardCAmaddeoGImbeaudSIntegrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinomaNat Genet201244669469822561517
   PubMed Web of Science ®Google Scholar
• FujimotoATotokiYAbeTWhole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulatorsNat Genet201244776076422634756
   PubMed Web of Science ®Google Scholar
• HuangJDengQWangQExome sequencing of hepatitis B virus-associated hepatocellular carcinomaNat Genet201244101117112122922871
   PubMed Web of Science ®Google Scholar
• KanZZhengHLiuXWhole-genome sequencing identifies recurrent mutations in hepatocellular carcinomaGenome Res20132391422143323788652
   PubMed Web of Science ®Google Scholar
• ClearySPJeckWRZhaoXIdentification of driver genes in hepatocellular carcinoma by exome sequencingHepatology20135851693170223728943
   PubMed Web of Science ®Google Scholar